$-0.44 EPS Expected for ACADIA Pharmaceuticals Inc. (ACAD)

July 14, 2018 - By Bradley Stiles

Investors sentiment decreased to 0.89 in Q1 2018. Its down 0.37, from 1.26 in 2017Q4. It fall, as 24 investors sold ACADIA Pharmaceuticals Inc. shares while 59 reduced holdings. 21 funds opened positions while 53 raised stakes. 119.37 million shares or 1.72% more from 117.35 million shares in 2017Q4 were reported.
Rhenman Prtn Asset Management Ab has 0.75% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 270,000 shares. Glenmede Trust Communication Na stated it has 207 shares. Alyeska Investment Group L P has invested 0.13% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Garrison Bradford & Associates invested 1.32% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Qs Investors Limited Liability Com reported 1,817 shares. Meeder Asset Management invested in 0% or 124 shares. 1.93M are owned by Jpmorgan Chase And. Principal Group Inc holds 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 34,585 shares. Victory Capital Mngmt reported 0% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). New York State Common Retirement Fund reported 0.01% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Zurcher Kantonalbank (Zurich Cantonalbank) reported 0% stake. Qvt Fincl L P has invested 0.07% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). National Bank Of America De stated it has 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Swiss Bancorp holds 173,404 shares or 0% of its portfolio. Eventide Asset Ltd owns 113,600 shares for 0.12% of their portfolio.

Since January 29, 2018, it had 1 buy, and 1 sale for $949,145 activity. SOLAND DANIEL B had bought 10,000 shares worth $234,910 on Thursday, March 1.

Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report $-0.44 EPS on August, 14.They anticipate $0.11 EPS change or 20.00 % from last quarter’s $-0.55 EPS. After having $-0.44 EPS previously, ACADIA Pharmaceuticals Inc.’s analysts see 0.00 % EPS growth. The stock decreased 1.69% or $0.3 during the last trading session, reaching $17.46. About 2.45 million shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 32.66% since July 14, 2017 and is downtrending. It has underperformed by 45.23% the S&P500.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Ratings Coverage

Among 2 analysts covering ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ACADIA Pharmaceuticals Inc had 2 analyst reports since April 10, 2018 according to SRatingsIntel. Needham maintained it with “Buy” rating and $4900 target in Tuesday, April 10 report. Cowen & Co maintained ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) rating on Tuesday, April 10. Cowen & Co has “Buy” rating and $5000 target.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $2.18 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

More notable recent ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) news were published by: Businesswire.com which released: “Glancy Prongay & Murray LLP Announces Investigation on Behalf of ACADIA Pharmaceuticals Inc. Investors (ACAD)” on July 13, 2018, also Benzinga.com with their article: “PreMarket Prep Recap For July 5: Trading The Range In The S&P 500; Sean Udall Joins The Show” published on July 05, 2018, Globenewswire.com published: “Bragar Eagel & Squire, PC is Investigating ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on Behalf of Stockholders …” on July 09, 2018. More interesting news about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) were released by: Prnewswire.com and their article: “Hagens Berman Alerts Investors in ACADIA Pharmaceuticals Inc. (ACAD) to the Firm’s Investigation of Possible …” published on July 11, 2018 as well as Seekingalpha.com‘s news article titled: “Acadia Pharma +12% after FDA approves dosing, strength for Nuplazid” with publication date: June 29, 2018.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: